Search Results - "Wilmink, J W"

Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer by Strijker, M., Chen, J. W., Mungroop, T. H., Jamieson, N. B., van Eijck, C. H., Steyerberg, E. W., Wilmink, J. W., Groot Koerkamp, B., van Laarhoven, H. W., Besselink, M. G.

“…Background As more therapeutic options for pancreatic cancer are becoming available, there is a need to improve outcome prediction to support shared…”
Get full text

Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment by Vuijk, F. A., de Muynck, L. D. A. N., Franken, L. C., Busch, O. R., Wilmink, J. W., Besselink, M. G., Bonsing, B. A., Bhairosingh, S. S., Kuppen, P. J. K., Mieog, J. S. D., Sier, C. F. M., Vahrmeijer, A. L., Verheij, J., Fariňa-Sarasqueta, A., Swijnenburg, R. J.

“…Neoadjuvant systemic treatment is increasingly being integrated in the standard treatment of pancreatic ductal adenocarcinoma (PDAC) patients to improve…”
Get full text

Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study by Moekotte, A L, Malleo, G, van Roessel, S, Bonds, M, Halimi, A, Zarantonello, L, Napoli, N, Dreyer, S B, Wellner, U F, Bolm, L, Mavroeidis, V K, Robinson, S, Khalil, K, Ferraro, D, Mortimer, M C, Harris, S, Al-Sarireh, B, Fusai, G K, Roberts, K J, Fontana, M, White, S A, Soonawalla, Z, Jamieson, N B, Boggi, U, Alseidi, A, Shablak, A, Wilmink, J W, Primrose, J N, Salvia, R, Bassi, C, Besselink, M G, Abu Hilal, M

“…Abstract Background Whether patients who undergo resection of ampullary adenocarcinoma have a survival benefit from adjuvant chemotherapy is currently unknown…”
Get full text

Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design by Daamen, L A, van Goor, I W J M, Groot, V P, Andel, P C M, Brosens, L A A, Busch, O R, Cirkel, G A, Mohammad, N Haj, Heerkens, H D, de Hingh, I H J T, Hoogwater, F, van Laarhoven, H W M, Los, M, Meijer, G J, de Meijer, V E, Pande, R, Roberts, K J, Stoker, J, Stommel, M W J, van Tienhoven, G, Verdonk, R C, Verkooijen, H M, Wessels, F J, Wilmink, J W, Besselink, M G, van Santvoort, H C, Intven, M P W, Molenaar, I Q

“…Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic…”
Get full text

Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design by Daamen, L A, van Goor, I W J M, Groot, V P, Andel, P C M, Brosens, L A A, Busch, O R, Cirkel, G A, Mohammad, N Haj, Heerkens, H D, de Hingh, I H J T, Hoogwater, F, van Laarhoven, H W M, Los, M, Meijer, G J, de Meijer, V E, Pande, R, Roberts, K J, Stoker, J, Stommel, M W J, van Tienhoven, G, Verdonk, R C, Verkooijen, H M, Wessels, F J, Wilmink, J W, Besselink, M G, van Santvoort, H C, Intven, M P W, Molenaar, I Q

Get full text

Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort by Doppenberg, D, Lagerwaard, F J, van Dieren, S, Meijerink, M R, van der Vliet, J J, Besselink, M G, van Tienhoven, G, Versteijne, E, Slotman, B J, Wilmink, J W, Kazemier, G, Bruynzeel, A M E

“…The role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is…”
Get full text

Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report by Haenen, S M, Tol, J A M G, van Steen, S C J, Busch, O R, Sarasqueta, A Farine, Roshani, S, Wolkerstorfer, A, van der Linden, M M D, Wilmink, J W, Post, H C, Besselink, M G

“…Pancreatic panniculitis is characterized by subcutaneous fat necrosis and is a rare presentation of an underlying pancreatic disease, appearing in…”
Get full text

Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care by Willems, R A L, Michiels, N, Lanting, V R, Bouwense, S, van den Broek, B L J, Graus, M, Klok, F A, Groot Koerkamp, B, de Laat, B, Roest, M, Wilmink, J W, van Es, N, Mieog, J S D, Ten Cate, H, de Vos-Geelen, J

“…Recent studies have shown that patients with pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant chemo(radio)therapy followed by surgery have an…”
Get full text

Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial by Walma, M S, Rombouts, S J, Brada, L J H, Borel Rinkes, I H, Bosscha, K, Bruijnen, R C, Busch, O R, Creemers, G J, Daams, F, van Dam, R M, van Delden, O M, Festen, S, Ghorbani, P, de Groot, D J, de Groot, J W B, Haj Mohammad, N, van Hillegersberg, R, de Hingh, I H, D'Hondt, M, Kerver, E D, van Leeuwen, M S, Liem, M S, van Lienden, K P, Los, M, de Meijer, V E, Meijerink, M R, Mekenkamp, L J, Nio, C Y, Oulad Abdennabi, I, Pando, E, Patijn, G A, Polée, M B, Pruijt, J F, Roeyen, G, Ropela, J A, Stommel, M W J, de Vos-Geelen, J, de Vries, J J, van der Waal, E M, Wessels, F J, Wilmink, J W, van Santvoort, H C, Besselink, M G, Molenaar, I Q

“…Approximately 80% of patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy, of whom approximately 10% undergo a resection…”
Get full text

Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer by Geest, Lydia G. M., Haj Mohammad, Nadia, Besselink, Marc G. H., Lemmens, Valery E. P. P., Portielje, Johanneke E. A., Laarhoven, Hanneke W. M., Wilmink, J. (Hanneke) W.

“…Despite an aging population and underrepresentation of elderly patients in clinical trials, studies on elderly patients with metastatic pancreatic cancer are…”
Get full text

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer by Versteijne, E., Vogel, J. A., Besselink, M. G., Busch, O. R. C., Wilmink, J. W., Daams, J. G., van Eijck, C. H. J., Groot Koerkamp, B., Rasch, C. R. N., van Tienhoven, G.

“…Background Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival…”
Get full text

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study by Rombouts, S J, Mungroop, T H, Heilmann, M N, van Laarhoven, H W, Busch, O R, Molenaar, I Q, Besselink, M G, Wilmink, J W

“…FOLFIRINOX is emerging as new standard of care for fit patients with locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer (MPC). However,…”
Get full text

The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer by van Es, N, Franke, V, Middeldorp, S, Wilmink, J.W, Büller, H.R

“…Abstract Background The Khorana score is a clinical prediction score developed to identify ambulatory cancer patients at high risk of venous thromboembolism…”
Get full text

Gender differences in tumor characteristics, treatment allocation and survival in stage I–III pancreatic cancer: a nationwide study by Gehrels, A.M., Wagner, A.D., Besselink, M.G., Verhoeven, R.H.A., van Eijck, C.H.J., van Laarhoven, H.W.M., Wilmink, J.W., van der Geest, L.G.

“…Sex and gender are modulators of health and disease and may have impact on treatment allocation and survival in patients with cancer. In this study, we…”
Get full text

Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis by Creemers, A., Krausz, S., Strijker, M., van der Wel, M.J., Soer, E.C., Reinten, R.J., Besselink, M.G., Wilmink, J.W., van de Vijver, M.J., van Noesel, C.J.M., Verheij, J., Meijer, S.L., Dijk, F., Bijlsma, M.F., van Oijen, M.G.H., van Laarhoven, H.W.M.

“…The recent expanding technical possibilities to detect tumor derived mutations in blood, so-called circulating tumor DNA (ctDNA), has rapidly increased the…”
Get full text

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer by Kordes, S., Klümpen, H. J., Weterman, M. J., Schellens, J. H. M., Richel, D. J., Wilmink, J. W.

“…Purpose The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between…”
Get full text

Postoperative surveillance of pancreatic cancer patients by Daamen, L.A., Groot, V.P., Intven, M.P.W., Besselink, M.G., Busch, O.R., Koerkamp, B. Groot, Mohammad, N. Haj, Hermans, J.J., van Laarhoven, H.W.M., Nuyttens, J.J., Wilmink, J.W., van Santvoort, H.C., Molenaar, I.Q., Stommel, M.W.J.

“…The aim of this study is to collect the best available evidence for diagnostic modalities, frequency, and duration of surveillance after resection for…”
Get full text

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials by Belkouz, A., Wilmink, J.W., Haj Mohammad, N., Hagendoorn, J., de Vos-Geelen, J., Dejong, C.H.C., Homs, M.Y.V., Groot Koerkamp, B., van Gulik, T.M., van Oijen, M.G.H., Punt, C.J.A., Klümpen, H.

“…Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve…”
Get full text

Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands by Haj Mohammad, N., Bernards, N., Besselink, M. G. H., Busch, O. R., Wilmink, J. W., Creemers, G. J. M., De Hingh, I. H. J. T., Lemmens, V. E. P. P., van Laarhoven, H. W. M.

“…Purpose In pancreatic surgery, a relation between surgical volume and postoperative mortality and overall survival (OS) has been recognized, with high-volume…”
Get full text

Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design by Doppenberg, D, Besselink, M G, van Eijck, C H J, Intven, M P W, Groot Koerkamp, B, Kazemier, G, van Laarhoven, H W M, Meijerink, M, Molenaar, I Q, Nuyttens, J J M E, van Os, R, van Santvoort, H C, van Tienhoven, G, Verkooijen, H M, Versteijne, E, Wilmink, J W, Lagerwaard, F J, Bruynzeel, A M E

Get full text